CEST for Prostate Biopsy

ConditionProstate Cancer Detection

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexMale

Age18+

SponsorSunnybrook Health Sciences Centre

About this trial

Samples of prostate tissue acquired by biopsy to determine whether there is cancer will sometimes not find cancer that is present. Conventionally, magnetic resonance imaging (MRI) is used to identify 12 areas to biopsy. We will use an advanced MRI method called magnetization transfer (MT) and chemical exchange saturation transfer (CEST) imaging to suggest two additional biopsy location. Our objectives are to determine 1) whether MT/CEST MRI can aid in the detection prostate cancer and 2) whether MT/CEST MRI can aid conventional MRI in risk stratification and to decide whether targeted prostate biopsy is justified.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

PI-RADS category 3 prostate cancer with upcoming targeted biopsy

Disqualifiers

Contraindications to MRI

Prior radiotherapy

Prior chemotherapy

Prior prostate biopsy

Trial design

Design model

Single group

Treatments tested in this trial

Biopsy-Guided Therapy Selection
Procedure/Surgery
Saturation transfer MRI (chemical exchange saturation transfer and magnetization transfer) used to identify two additional biopsy locations in addition to those identified by conventional MRI.

Treatment groups

20 Participants

are divided into 1 treatment group

Group A: Diagnostic Test: Saturation Transfer (ST)-MRIExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Aiding the detection of prostate cancer

To determine whether MT/CEST MRI can aid in the detection of prostate cancer. The histopathological detection of cancer in biopsy cores will serve as a measure of outcome to which the MT/CEST MRI parameter and relaxation images will be compared.

Time frame

1 year

Secondary outcomes

Aiding risk stratification and the decision whether targeted prostate biopsy is justified

To determine whether MT/CEST MRI can aid multiparametric MRI (mpMRI) in risk stratification and to decide whether targeted prostate biopsy is justified. The presence of cancer detected histopathologically in biopsy locations suggested by MT/CEST MRI, but not chosen for biopsy by convention mpMRI will serve as a measure of outcome.

Time frame

1 year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sunnybrook Health Sciences Centre

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: